BR0314308A - Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto - Google Patents
Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um compostoInfo
- Publication number
- BR0314308A BR0314308A BR0314308-2A BR0314308A BR0314308A BR 0314308 A BR0314308 A BR 0314308A BR 0314308 A BR0314308 A BR 0314308A BR 0314308 A BR0314308 A BR 0314308A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- patient
- related diseases
- kappa
- delta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA BLOQUEAR UMA COMBINAçãO DE MU, KAPPA, DELTA OU RECEPTOR (HETERODìMERO) DOS MESMOS EM MAMìFEROS, PARA TRATAR OU PREVENIR OBESIDADE E DOENçAS RELACIONADAS, PARA SUPRIMIR O APETITE EM UM PACIENTE EM NECESSIDADE DESTE, E PARA REALIZAR A PERDA DE PESO EM UM PACIENTE OBESO, E, USO DE UM COMPOSTO". Um composto da fórmula (I) em que as variáveis X~ 1~ a X~ 10~, R^ 10^ a R^ 7^ incluindo R^ 3^, E, V, Y, Z, A e B são como descritas ou um sal farmaceuticamente aceitável, solvato, enantiómero, racemato, diasteroisómero ou misturas destes, úteis para o tratamento, prevenção ou melhora de obesidade e Doenças Relacionadas são divulgados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41215802P | 2002-09-19 | 2002-09-19 | |
US60/412,158 | 2002-09-19 | ||
PCT/US2003/026300 WO2004026305A1 (en) | 2002-09-19 | 2003-09-17 | Diaryl ethers as opioid receptor antagonist |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0314308A true BR0314308A (pt) | 2005-07-05 |
BRPI0314308B1 BRPI0314308B1 (pt) | 2018-06-19 |
BRPI0314308B8 BRPI0314308B8 (pt) | 2021-05-25 |
Family
ID=32030816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0314308A BRPI0314308B8 (pt) | 2002-09-19 | 2003-09-17 | antagonistas de opióide, seus usos, e composição farmacêutica |
Country Status (30)
Country | Link |
---|---|
US (3) | US7381719B2 (pt) |
EP (2) | EP2208727B1 (pt) |
JP (1) | JP4646628B2 (pt) |
KR (1) | KR101025633B1 (pt) |
CN (1) | CN1305852C (pt) |
AR (1) | AR042423A1 (pt) |
AT (1) | ATE395915T1 (pt) |
AU (1) | AU2008246245B2 (pt) |
BR (1) | BRPI0314308B8 (pt) |
CA (1) | CA2499690C (pt) |
CY (2) | CY1108228T1 (pt) |
DE (1) | DE60321207D1 (pt) |
DK (2) | DK1562595T3 (pt) |
EA (1) | EA008861B1 (pt) |
EC (1) | ECSP055684A (pt) |
ES (2) | ES2392200T3 (pt) |
HK (2) | HK1083188A1 (pt) |
HR (1) | HRP20050253B1 (pt) |
MX (1) | MXPA05003093A (pt) |
MY (1) | MY140236A (pt) |
NO (1) | NO330740B1 (pt) |
NZ (1) | NZ538459A (pt) |
PE (1) | PE20050080A1 (pt) |
PL (1) | PL212616B1 (pt) |
PT (2) | PT1562595E (pt) |
SI (2) | SI1562595T1 (pt) |
TW (1) | TWI287012B (pt) |
UA (1) | UA80437C2 (pt) |
WO (1) | WO2004026305A1 (pt) |
ZA (1) | ZA200502276B (pt) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6374762B1 (en) * | 1997-10-27 | 2002-04-23 | Correct Craft, Inc. | Water sport towing apparatus |
US20030170917A1 (en) * | 2002-03-01 | 2003-09-11 | Roche Diagnostics Corporation | Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes |
UA80437C2 (en) * | 2002-09-19 | 2007-09-25 | Lilly Co Eli | Diaryl ethers as opioid receptor antagonist |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1572215B1 (en) | 2002-12-20 | 2009-09-02 | Glaxo Group Limited | Benzo[d]azepine derivatives for the treatment of neurological disorders |
ES2294475T3 (es) | 2003-03-07 | 2008-04-01 | Eli Lilly And Company | Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides. |
CN1874991A (zh) | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
KR20110140139A (ko) | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
WO2005061442A1 (en) * | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
AU2004312312A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
CA2558652A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
WO2005090286A1 (en) * | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
CA2557794A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
EP1751103B1 (en) | 2004-03-15 | 2009-01-14 | Eli Lilly And Company | 4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
GB0408083D0 (en) * | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
PE20060115A1 (es) | 2004-07-23 | 2006-03-23 | Basf Ag | 2-(piridin-2-il)-pirimidinas como agentes fungicidas |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
EP2374455A3 (en) * | 2004-08-19 | 2012-03-28 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
RU2007124373A (ru) * | 2004-11-29 | 2009-01-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы мускариновых рецептеров |
BRPI0519012A2 (pt) * | 2004-12-13 | 2008-12-23 | Ono Pharmaceutical Co | derivado do Ácido aminocarboxÍlico e seu uso medicinal |
EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
EP1943226A2 (en) | 2005-10-13 | 2008-07-16 | Smithkline Beecham Corporation | Phenol ethers as modulators of the opioid receptors |
WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
JP2009519986A (ja) * | 2005-12-20 | 2009-05-21 | ノバルティス アクチエンゲゼルシャフト | 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体 |
US7858635B2 (en) * | 2005-12-22 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Spiro compounds as modulators of muscarinic receptors |
US8263605B2 (en) * | 2006-02-22 | 2012-09-11 | Vertex Pharmaceutical Incorporated | Modulators of muscarinic receptors |
EP1988892A2 (en) | 2006-02-22 | 2008-11-12 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
SG173312A1 (en) | 2006-06-23 | 2011-08-29 | Abbott Lab | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
US7858790B2 (en) * | 2006-06-29 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2008021849A2 (en) * | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
AU2007284548A1 (en) * | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
CN101573121A (zh) | 2006-08-18 | 2009-11-04 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
WO2008032156A1 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
MX2009004314A (es) * | 2006-11-13 | 2009-05-05 | Pfizer Prod Inc | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. |
US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
IL180134A0 (en) * | 2006-12-17 | 2007-07-04 | David Ovadia | Process for the preparation of substituted cyanophenoxy-pyrimidinyloxy -phenyl acrylate derivatives |
US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
EP2152671A1 (en) * | 2007-05-22 | 2010-02-17 | Prosidion Limited | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |
US8063247B2 (en) | 2007-09-07 | 2011-11-22 | Prosidion Limited | Bicyclic aryl and heteroaryl receptor modulators |
AU2008298926A1 (en) * | 2007-09-12 | 2009-03-19 | Wyeth Llc | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
AU2008307440A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
AR070158A1 (es) * | 2008-01-22 | 2010-03-17 | Lilly Co Eli | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa |
WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
MX342548B (es) * | 2009-09-18 | 2016-10-04 | Merck Sharp & Dohme Corp * | Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. |
WO2012064396A2 (en) | 2010-08-21 | 2012-05-18 | Georgetown University | Novel ezrin inhibitors and methods of making and using |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
WO2012075232A1 (en) * | 2010-12-04 | 2012-06-07 | Trevena, Inc. | Opioid receptor ligands and methods of using and making the same |
PL3290415T3 (pl) * | 2011-03-23 | 2021-07-19 | Trevena, Inc. | Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania |
GB201118876D0 (en) * | 2011-11-01 | 2011-12-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
ES2631607T3 (es) * | 2011-12-09 | 2017-09-01 | Research Triangle Institute, International | 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113788A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
AU2013214137A1 (en) | 2012-02-03 | 2014-08-21 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
EP2968265A4 (en) * | 2013-03-14 | 2016-12-28 | Celtaxsys Inc | INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE |
KR20180093930A (ko) | 2015-12-14 | 2018-08-22 | 트레베나, 인코포레이티드. | 통각과민증을 치료하는 방법 |
CN106117190B (zh) * | 2016-06-21 | 2019-03-29 | 山东川成医药股份有限公司 | 一种倍福普兰的合成方法 |
US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
CN108299411B (zh) * | 2017-01-13 | 2021-02-05 | 中国人民解放军军事医学科学院毒物药物研究所 | 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途 |
CA3052479A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
US11702408B2 (en) | 2017-02-17 | 2023-07-18 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
JP7234201B2 (ja) * | 2017-07-12 | 2023-03-07 | ブリストル-マイヤーズ スクイブ カンパニー | 心不全の治療のためのrockの5員アミノヘテロ環および5,6-または6,6員二環式アミノヘテロ環の阻害剤 |
WO2020039088A2 (en) * | 2018-08-24 | 2020-02-27 | Xeniopro GmbH | Novel compounds |
WO2023179542A1 (en) * | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4191771A (en) | 1974-09-06 | 1980-03-04 | Eli Lilly And Company | Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines |
SE417011B (sv) * | 1979-03-05 | 1981-02-16 | Saab Scania Ab | Malanordning |
US4346091A (en) * | 1980-05-27 | 1982-08-24 | Shell Oil Company | Insecticidal combinations |
US4422646A (en) * | 1981-09-18 | 1983-12-27 | Tvi Energy Corporation | Infrared target for military applications and its use |
US4546983A (en) * | 1981-09-18 | 1985-10-15 | Tvi Energy Corporation | Multi-spectral target |
US4659089A (en) * | 1981-09-18 | 1987-04-21 | Tvi Energy Corporation | Multi-spectral target |
US4891379A (en) | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
AR245933A1 (es) * | 1987-04-16 | 1994-03-30 | Lilly Co Eli | Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales. |
US4792142A (en) * | 1987-11-13 | 1988-12-20 | Davies Robert M | Thermal target device |
US5065032A (en) * | 1990-09-10 | 1991-11-12 | Custom Training Aids | Thermal integrated target |
US5319213A (en) * | 1992-04-06 | 1994-06-07 | The United States Of America As Represented By The Secretary Of The Army | Thermal target test board |
ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
DE69711519T2 (de) * | 1996-09-05 | 2002-10-31 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische Agonisten |
US5969369A (en) * | 1997-08-29 | 1999-10-19 | Fogarty; Charles M. | Infrared emissive module |
CO5011072A1 (es) * | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
SE9802209D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
US6436959B1 (en) * | 1998-12-23 | 2002-08-20 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(piperidin-4-yl)]aminobenzamides |
GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
US6337475B1 (en) * | 2000-02-24 | 2002-01-08 | The United States Of America As Represented By The Secretary Of The Army | Thermal silhouette target and zeroing technique |
PE20020195A1 (es) * | 2000-07-13 | 2002-03-12 | Lilly Co Eli | AGONISTAS ß3 ADRENERGICOS |
JP2004513164A (ja) | 2000-11-10 | 2004-04-30 | イーライ・リリー・アンド・カンパニー | 3−置換オキシインドールβ3アゴニスト |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
ATE372768T1 (de) | 2001-03-29 | 2007-09-15 | Lilly Co Eli | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste |
GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
UA80437C2 (en) * | 2002-09-19 | 2007-09-25 | Lilly Co Eli | Diaryl ethers as opioid receptor antagonist |
BRPI0408108A (pt) | 2003-03-07 | 2006-03-01 | Lilly Co Eli | composto, composição farmacêutica, métodos para bloquear em receptor mu, kappa, delta ou uma combinação de receptores dos mesmos em um mamìfero, para tratar ou prevenir obesidade e doenças relacionadas e para suprimir apetite, e, uso de um composto |
ES2294475T3 (es) | 2003-03-07 | 2008-04-01 | Eli Lilly And Company | Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides. |
US6767015B1 (en) * | 2003-06-05 | 2004-07-27 | The United States Of America As Represented By The Secretary Of The Navy | Thermal target |
WO2005061442A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
AU2004312312A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
WO2005090286A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
CA2558652A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
CA2557794A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
EP1751103B1 (en) | 2004-03-15 | 2009-01-14 | Eli Lilly And Company | 4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
-
2003
- 2003-09-17 UA UAA200502384A patent/UA80437C2/uk unknown
- 2003-09-17 NZ NZ538459A patent/NZ538459A/en not_active IP Right Cessation
- 2003-09-17 EP EP08153866A patent/EP2208727B1/en not_active Expired - Lifetime
- 2003-09-17 SI SI200331282T patent/SI1562595T1/sl unknown
- 2003-09-17 AR ARP030103376A patent/AR042423A1/es active IP Right Grant
- 2003-09-17 DK DK03751877T patent/DK1562595T3/da active
- 2003-09-17 ES ES08153866T patent/ES2392200T3/es not_active Expired - Lifetime
- 2003-09-17 SI SI200332196T patent/SI2208727T1/sl unknown
- 2003-09-17 MY MYPI20033546A patent/MY140236A/en unknown
- 2003-09-17 EA EA200500508A patent/EA008861B1/ru unknown
- 2003-09-17 BR BRPI0314308A patent/BRPI0314308B8/pt active IP Right Grant
- 2003-09-17 EP EP03751877A patent/EP1562595B1/en not_active Expired - Lifetime
- 2003-09-17 AT AT03751877T patent/ATE395915T1/de active
- 2003-09-17 MX MXPA05003093A patent/MXPA05003093A/es active IP Right Grant
- 2003-09-17 JP JP2004537682A patent/JP4646628B2/ja not_active Expired - Lifetime
- 2003-09-17 PT PT03751877T patent/PT1562595E/pt unknown
- 2003-09-17 PL PL376057A patent/PL212616B1/pl unknown
- 2003-09-17 DE DE60321207T patent/DE60321207D1/de not_active Expired - Lifetime
- 2003-09-17 WO PCT/US2003/026300 patent/WO2004026305A1/en active Application Filing
- 2003-09-17 ES ES03751877T patent/ES2305491T3/es not_active Expired - Lifetime
- 2003-09-17 CN CNB038222418A patent/CN1305852C/zh not_active Expired - Lifetime
- 2003-09-17 PT PT08153866T patent/PT2208727E/pt unknown
- 2003-09-17 CA CA2499690A patent/CA2499690C/en not_active Expired - Lifetime
- 2003-09-17 KR KR1020057004628A patent/KR101025633B1/ko active IP Right Grant
- 2003-09-17 DK DK08153866.2T patent/DK2208727T3/da active
- 2003-09-17 US US10/526,960 patent/US7381719B2/en active Active
- 2003-09-18 PE PE2003000959A patent/PE20050080A1/es active IP Right Grant
- 2003-09-18 TW TW092125729A patent/TWI287012B/zh not_active IP Right Cessation
-
2005
- 2005-03-17 HR HRP20050253AA patent/HRP20050253B1/hr not_active IP Right Cessation
- 2005-03-17 EC EC2005005684A patent/ECSP055684A/es unknown
- 2005-03-17 ZA ZA200502276A patent/ZA200502276B/en unknown
- 2005-04-18 NO NO20051871A patent/NO330740B1/no not_active IP Right Cessation
-
2006
- 2006-02-16 HK HK06102045A patent/HK1083188A1/xx not_active IP Right Cessation
-
2008
- 2008-03-21 US US12/052,994 patent/US7560463B2/en not_active Expired - Lifetime
- 2008-03-21 US US12/052,972 patent/US7531557B2/en not_active Expired - Lifetime
- 2008-07-30 CY CY20081100798T patent/CY1108228T1/el unknown
- 2008-11-19 AU AU2008246245A patent/AU2008246245B2/en not_active Expired
-
2010
- 2010-09-15 HK HK10108780.5A patent/HK1142322A1/xx not_active IP Right Cessation
-
2012
- 2012-10-25 CY CY20121101016T patent/CY1113362T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
BRPI0407616A (pt) | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" | |
BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
BR0317717A (pt) | Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto | |
BRPI0508107A (pt) | derivados de indazol e composições farmacêuticas contendo os mesmos | |
IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
BRPI0408784A (pt) | método para usar um composto | |
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
BR0315580A (pt) | Derivados de metileno uréia | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
BRPI0417156A (pt) | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso | |
BR0306919A (pt) | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
DK1784173T3 (da) | Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater | |
BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |